Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Capital Wealth Planning LLC

Capital Wealth Planning LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 161,350 shares of the company’s stock after acquiring an additional 7,620 shares during the quarter. Capital Wealth Planning LLC’s holdings in Teva Pharmaceutical Industries were worth $2,622,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TEVA. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $30,000. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries in the second quarter worth $48,000. Byrne Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter worth $52,000. Finally, Industrial Alliance Investment Management Inc. acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 2.2 %

NYSE:TEVA opened at $18.41 on Monday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a 1-year low of $8.06 and a 1-year high of $19.08. The firm has a market capitalization of $20.86 billion, a price-to-earnings ratio of -44.90, a price-to-earnings-growth ratio of 1.26 and a beta of 0.88. The stock has a fifty day simple moving average of $17.55 and a 200 day simple moving average of $15.95.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TEVA shares. Jefferies Financial Group increased their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. Bank of America raised their price target on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Barclays raised their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.